Kondo, Y., Ohashi, S., Katada, C., Nakai, Y., Yamamoto, Y., Tamaoki, M., Kikuchi, O., Yamada, A., Hirohashi, K., Mitani, Y., Kataoka, S., Saito, T., Vu, T. H. N., Kondo, T., Uneno, Y., Sunami, T., Yokoyama, A., Matsubara, J., Matsuda, T., … Muto, M. (2025). Aldh2 and the tumor suppressor Trp53 play important roles in alcohol-induced squamous field cancerization. Journal of Gastroenterology. https://doi.org/10.1007/s00535-024-02210-y

de Queiroz, R. M., Efe, G., Guzman, A., Hashimoto, N., Kawashima, Y., Tanaka, T., Rustgi, A. K., & Prives, C. (2024). Mdm2 requires Sprouty4 to regulate focal adhesion formation and metastasis independent of p53. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-51488-2

Galanti, L., Peritore, M., Gnügge, R., Cannavo, E., Heipke, J., Palumbieri, M. D., Steigenberger, B., Symington, L. S., Cejka, P., & Pfander, B. (2024). Dbf4-dependent kinase promotes cell cycle controlled resection of DNA double-strand breaks and repair by homologous recombination. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-46951-z

Goodwin, P. J., Chen, B. E., Gelmon, K. A., Whelan, T. J., Ennis, M., Lemieux, J., Ligibel, J. A., Hershman, D. L., Mayer, I. A., Hobday, T. J., Bliss, J. M., Rastogi, P., Rabaglio-Poretti, M., Thompson, A. M., Rea, D. W., Stos, P. M., Shepherd, L. E., Stambolic, V., & Parulekar, W. R. (2023). Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer. Journal of Clinical Oncology, 41(35), 5356–5362. https://doi.org/10.1200/jco.23.00296

Wu-Baer, F., Wong, M., Tschoe, L., Lin, C.-S., Jiang, W., Zha, S., & Baer, R. (2023). ATM/ATR Phosphorylation of CtIP on Its Conserved Sae2-like Domain Is Required for Genotoxin-Induced DNA Resection but Dispensable for Animal Development. Cells, 12(23), 2762. https://doi.org/10.3390/cells12232762

Kim, S., Armand, J., Safonov, A., Zhang, M., Soni, R. K., Schwartz, G., McGuinness, J. E., Hibshoosh, H., Razavi, P., Kim, M., Chandarlapaty, S., & Yang, H. W. (2023). Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer. Cell Reports, 42(11), 113198. https://doi.org/10.1016/j.celrep.2023.113198

Trauernicht, M., Rastogi, C., Manzo, S. G., Bussemaker, H. J., & van Steensel, B. (2023). Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements. Nucleic Acids Research, 51(18), 9690–9702. https://doi.org/10.1093/nar/gkad718

Li, F., Chen, D., Sun, Q., Wu, J., Gan, Y., Leong, K. W., & Liang, X. (2023). MDM2‐Targeting Reassembly Peptide (TRAP) Nanoparticles for p53‐Based Cancer Therapy. Advanced Materials, 35(45). Portico. https://doi.org/10.1002/adma.202305164

Awah, C. U., Glemaud, Y., Levine, F., Yang, K., Ansary, A., Dong, F., Ash, L., Zhang, J., & Ogunwobi, O. O. (2023). Destabilized 3’UTR elements therapeutically degrade ERBB2 mRNA in drug-resistant ERBB2+ cancer models. Frontiers in Genetics, 14. https://doi.org/10.3389/fgene.2023.1184600

Ong, H. W., Liang, Y., Richardson, W., Lowry, E. R., Wells, C. I., Chen, X., Silvestre, M., Dempster, K., Silvaroli, J. A., Smith, J. L., Wichterle, H., Pabla, N. S., Ultanir, S. K., Bullock, A. N., Drewry, D. H., & Axtman, A. D. (2023). Discovery of a Potent and Selective CDKL5/GSK3 Chemical Probe That Is Neuroprotective. ACS Chemical Neuroscience, 14(9), 1672–1685. https://doi.org/10.1021/acschemneuro.3c00135

Fine, R. L., Mao, Y., Garcia-Carracedo, D., Su, G. H., Qiu, W., Hochfeld, U., Nichols, G., Li, Y.-L., Dinnen, R. D., Raffo, A., & Brandt-Rauf, P. W. (2023). Gene Therapy with p14/tBID Induces Selective and Synergistic Apoptosis in Mutant Ras and Mutant p53 Cancer Cells In Vitro and In Vivo. Biomedicines, 11(2), 258. https://doi.org/10.3390/biomedicines11020258

Fine, R. L., Mao, Y., Dinnen, R., Rosal, R. V., Raffo, A., Hochfeld, U., Senatus, P., Bruce, J. N., Nichols, G., Wang, H., Li, Y., & Brandt-Rauf, P. W. (2023). C-Terminal p53 Palindromic Tetrapeptide Restores Full Apoptotic Function to Mutant p53 Cancer Cells In Vitro and In Vivo. Biomedicines, 11(1), 137. https://doi.org/10.3390/biomedicines11010137

Caspa Gokulan, R., Paulrasu, K., Azfar, J., El-Rifai, W., Que, J., Boutaud, O. G., Ban, Y., Gao, Z., Buitrago, M. G., Dikalov, S. I., & Zaika, A. I. (2023). Protein adduction causes non-mutational inhibition of p53 tumor suppressor. Cell Reports, 42(1), 112024. https://doi.org/10.1016/j.celrep.2023.112024

Filippone, M. G., Gaglio, D., Bonfanti, R., Tucci, F. A., Ceccacci, E., Pennisi, R., Bonanomi, M., Jodice, G., Tillhon, M., Montani, F., Bertalot, G., Freddi, S., Vecchi, M., Taglialatela, A., Romanenghi, M., Romeo, F., Bianco, N., Munzone, E., Sanguedolce, F., … Pece, S. (2022). CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-30375-8

Kim, S., Leong, A., Kim, M., & Yang, H. W. (2022). CDK4/6 initiates Rb inactivation and CDK2 activity coordinates cell-cycle commitment and G1/S transition. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-20769-5

Mukherjee, S., Ali, A. M., Murty, V. V., & Raza, A. (2022). Mutation in SF3B1 gene promotes formation of polyploid giant cells in Leukemia cells. Medical Oncology, 39(6). https://doi.org/10.1007/s12032-022-01652-9

Diamond, J. R., Boni, V., Lim, E., Nowakowski, G., Cordoba, R., Morillo, D., Valencia, R., Genvresse, I., Merz, C., Boix, O., Frigault, M. M., Greer, J. M., Hamdy, A. M., Huang, X., Izumi, R., Wong, H., & Moreno, V. (2022). First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy. Clinical Cancer Research, 28(7), 1285–1293. https://doi.org/10.1158/1078-0432.ccr-21-3617